We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Tarveda Therapeutics, Inc today announced that it has dosed the first patient in a Phase 1/2a study evaluating PEN-866 in patients with advanced solid tumors.